Comparison

A10.7 cells

Item no. C0018006
Manufacturer Addexbio
Amount One Frozen vial
Category
Type Tumour Cells
Specific against Human (Homo sapiens)
Dry ice Yes
Citations 1.Bisht, S., Brossart, P., Maitra, A., and Feldmann, G. Agents targeting the Hedgehog pathway for pancreatic cancer treatment using A10.7 cells. Curr Opin Investig Drugs, 11: 1387-1398.
2.Feldmann, G., Fendrich, V., McGovern, K., Bedja, D., Bisht, S., Alvarez, H., Koorstra, J. B., Habbe, N., Karikari, C., Mullendore, M., Gabrielson, K. L., Sharma, R., Matsui, W., and Maitra, A. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer using A10.7 cells. Mol Cancer Ther, 7: 2725-2735, 2008.
3.Feldmann, G., Habbe, N., Dhara, S., Bisht, S., Alvarez, H., Fendrich, V., Beaty, R., Mullendore, M., Karikari, C., Bardeesy, N., Ouellette, M. M., Yu, W., and Maitra, A. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer using A10.7 cells. Gut, 57: 1420-1430, 2008.
4.Feldmann, G., Dhara, S., Fendrich, V., Bedja, D., Beaty, R., Mullendore, M., Karikari, C., Alvarez, H., Iacobuzio-Donahue, C., Jimeno, A., Gabrielson, K. L., Matsui, W., and Maitra, A. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases using A10.7 cells: a new paradigm for combination therapy in solid cancers. Cancer Res, 67: 2187-2196, 2007.
5. Embuscado EE, Laheru D, Ricci F, Yun KJ, de Boom Witzel S, Seigel A, Flickinger K, Hidalgo M, Bova GS, Iacobuzio-Donahue CA. Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther. 4(5):548-54, 2005.
ECLASS 10.1 32160890
ECLASS 11.0 32160890
UNSPSC 41106509
Available
Description

Disease:

Pancreatic adenocarcinoma

Origin:

Derived from metastatic liver tumor (clinical stage IV)

Species:

Homo sapiens

Tissue:

Pancreas

Morphology:

Epithelial

Properties:

Adherent

Cytogenic data:

Tumorigenic in xenograft model, KRAS mutation: G12D, p53 mutation: WT, SMAD4 mutation: homozygous deletion.

Patient:

Male, Caucasian, 60 yrs of age

Medium:

AddexBio-formulated DMEM (C0003-01) + 10% FBS

Subculture:

1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C

Freezing Medium:

Complete culture medium supplemented with 5% (v/v) DMSO

Biosafety Level:

I

Sterility:

Bacteria: Negative

Yeast: Negative

Mycoplasma: Negative

Pathogens:

HIV: Negative

Hepatitis B: Negative

Hepatitis C: Negative

Related cells by Organ:

AR-42J cells

BxPc-3 cells

Capan-1 cells

MIA PaCa-2 cells

E3LZ10.7 cells

A10.7 cells

INS-1 cells

MIN-6 cells

Storage condition
LN2
Manufacturers Category
Cell Lines

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: One Frozen vial
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close